Description
Fluzoparib is a PARP (poly ADP-ribose polymerase) inhibitor used in the treatment of certain cancers, particularly those with homologous recombination deficiency. It is primarily indicated for ovarian cancer and other solid tumors that harbor BRCA mutations or exhibit DNA repair pathway defects.
Mechanism of Action
Fluzoparib works by inhibiting PARP enzymes, which are essential for DNA single-strand break repair, leading to accumulation of DNA damage and synthetic lethality in cancer cells with defective homologous recombination repair mechanisms.
Side Effects
Nausea
Fatigue
Anemia
Thrombocytopenia
Neutropenia
Vomiting
Decreased appetite
Diarrhea
And increased risk of secondary malignancies
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06208410
Phase 1
Recruiting
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
China
NCT06516445
Phase 2
Recruiting
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
China